ArticleAnnals of medicine and surgery (2012)2025
Incidence and mortality trend of liver cancer in Iran from 1990 to 2021: an epidemiological investigation using the Global Burden of Disease study.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of liver cancer across the world is one of the most concerning. Iran, as a developing country, lacks a comprehensive review of liver cancer burden in recent years. This study aimed to evaluate the changing burden of liver cancer in Iran from 1990 to 2021. Methods: Data were extracted from the Global Burden of Disease study. Age-standardized incidence and mortality rates (ASIR, ASMR) were the main metrics used in this study. Average annual percent change (AAPC) was calculated for Iran and each province. Results: Liver cancer incidence rate in Iran increased to 2.70 [2.39 to 3.04] per 100 000 population in 2021 with an AAPC of 0.85 [0.61 to 1.08]. Mortality of liver cancer in 2021 increased to 2.87 [2.55 to 3.23], representing an AAPC of 0.83 [0.32 to 1.35]. Men faced a higher burden than women. The burden of liver cancer became more prominent with increasing age. The Incidence of NASH-related liver cancer shifted remarkably during the studied time period, surpassing trends of other risk factors (AAPC: 1.89 [1.75 to 2.03]). Ardebil showed the most significant increasing trends in incidence and mortality rates compared to other provinces. Incidence of liver cancer remained low in lower SDI provinces but gradually increased when moving towards high SDI ones, suggesting a positive correlation. Conclusion: This study highlights the concern for liver cancer rate and related death in Iran due to increasing shifts in mortality rates and deaths. Iranian policymakers must implement feasible preventive approaches to control liver cancer's major risk factors, such as NASH and Alcohol use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.